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Abstract Cystathionine β-synthase (CBS) deficiency is usu-
ally confirmed by assaying the enzyme activity in cultured skin
fibroblasts. We investigated whether CBS is present in human
plasma and whether determination of its activity in plasma
could be used for diagnostic purposes. We developed an assay
to measure CBS activity in 20 μL of plasma using a stable
isotope substrate - 2,3,3-
2H serine. The activity was deter-
mined by measurement of the product of enzyme reaction,
3,3-
2H-cystathionine, using LC-MS/MS. The median enzyme
activity in control plasma samples was 404 nmol/h/L (range
66–1,066; n=57). In pyridoxine nonresponsive CBS deficient
patients, the median plasma activity was 0 nmol/ho/L (range
0–9; n=26), while in pyridoxine responsive patients the
median activity was 16 nmol/hour/L (range 0–358; n=28);
this overlapped with the enzyme activity from control subject.
T h ep r e s e n c eo fC B Si nh u m a np l a s m aw a sc o n f i r m e db ya n
in silico search of the proteome database, and was further
evidenced by the activation of CBS by S-adenosyl-L-
methionine and pyridoxal 5′-phosphate, and by configuration
of the detected reaction product, 3,3-
2H-cystathionine, which
was in agreement with the previously observed CBS reaction
mechanism. We hypothesize that the CBS enzyme in plasma
originates from liver cells, as the plasma CBS activities in
patients with elevated liver aminotransferase activities were
more than 30-fold increased. In this study, we have
demonstrated that CBS is present in human plasma and that
its catalytic activity is detectable by LC-MS/MS. CBS assay
in human plasma brings new possibilities in the diagnosis of
pyridoxine nonresponsive CBS deficiency.
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Cystathionine β-synthase (CBS; EC 4.2.1.22) (http://www.
chem.qmul.ac.uk/iubmb/enzyme/EC4/2/1/22.html)d e f i -
ciency (http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?
id=236200) is a well-known genetic disease affecting the
first step in the conversion of homocysteine to cysteine and
ultimately to inorganic sulfur. Although this disorder was
originally considered a severe multisystem disease that
affected connective tissue and central nervous and vascular
systems (Mudd et al. 1985), recent reports suggest that an
unknown proportion of patients with CBS deficiency may
suffer from only a mild vascular form of the disease or may
be asymptomatic (Gaustadnes et al. 2000; Skovby et al.
2010). Diagnostic hallmarks of this disease are grossly
elevated concentrations of plasma total homocysteine
combined with decreased plasma concentrations of cysteine
and cystathionine (Stabler et al. 1993) with varying
elevations of plasma methionine levels. The DNA analysis
may be used to confirm the diagnosis only if mutations with
known pathogenicity are found at both patient CBS alleles;
its utility is limited in other situations.
Demonstration of decreased enzyme activity is a
common diagnostic approach in patients suffering from
inborn errors of metabolism (IEM) including CBS defi-
ciency. Since the majority of enzymes relevant for IEMs are
located intracellularly, the determination of enzymatic
activity requires in most cases sampling of patient tissue
ranging from simple venepuncture to biopsies of skin or
organs, such as the liver. In addition, laborious, time-
consuming and technically demanding culturing of tissue
such as skin may be required to produce sufficient amounts
of cells to express the enzyme of interest. However, these
intracellular enzymes can be released in small amounts
into plasma reflecting turnover of the respective tissue(s).
The amounts of these non-plasma-specific enzymes in
body fluids may increase if cell integrity is impaired;
clinical chemistry laboratories utilize this phenomenon
and routinely analyze activities of liver-, pancreatic-,
muscle-, myocardial-, prostatic- and other organ-specific
enzymes as biomarkers of diseases (Bhagavan 2001).
Determination of enzymes in extracellular fluids is only
rarely used for routine diagnostic purposes in IEMs (e.g.,
biotinidase or total hexosaminidase).
In our study, we hypothesized that CBS may be released
into plasma from organs expressing this enzyme and that its
activity may be measurable by a sensitive LC-MS/MS
assay employing deuterium-labeled substrates. To explore
this hypothesis, we studied the CBS catalytic activity of
plasma and stimulatory effect of CBS ligands, the presence
of the CBS protein by immunological and by an in silico
search, and its possible release to plasma from liver and
other organs. Finally, we assessed plasma CBS activity in
samples from patients with confirmed CBS deficiency to
assess the diagnostic utility of this assay.
Materials and methods
Chemicals
All chemicals, if not stated otherwise, were obtained from
Sigma–Aldrich (Prague)
Plasma samples
Archived anonymized plasma samples from controls and
patients with CBS deficiency were obtained from the
authors’ repositories in the Netherlands, UK, Ireland and
the Czech Republic. With the exception of 2 individuals, all
patients were treated with pyridoxine at the time of
sampling, regardless of their pyridoxine responsiveness
(for details see Supplementary Table).
Anonymized samples from individuals with presumed
liver, pancreatic and kidney disease (i.e., with elevated
plasma levels of alanine aminotransferase, α-amylase and
creatinine) were obtained as remnant samples after routine
biochemical investigations from the Institute of Clinical
Biochemistry and Laboratory Diagnostics of the General
Faculty Hospital and The First Medical Faculty of Charles
University. All experiments performed using human plasma
samples were approved by the Ethics Committee of the
General University Hospital, Prague.
Apparatus
The LC-MS/MS system consisted of an Agilent 1100 Series
LC System (Agilent Technologies, Palo Alto, CA, USA)
coupled with API 3200 triple quadrupole mass spectrom-
eter with electron ion source and operated with Analyst
software, Vision 1.4 (Applied Biosystems, Foster City, CA,
USA).
Sample preparation
To 25 μL of solution containing 200 mmol/L Tris-HCl (pH
8.6), 1 mmol/L pyridoxal 5′-phosphate and 40 mmol/L
2,3,3-
2H-labeled serine (Cambridge Isotope Laboratories,
USA), 20 μL of plasma or serum was added. The assay was
initiated by addition of 5 μL starting solution containing
280 mmol/L homocysteine thiolactone in 100 mmol/L Tris-
HCl (pH 8.6), 10 mmol/L DTT, 1 mol/L HCl and
1.225 mol/L NaOH. This starting solution was prepared
freshly before sample processing and was preincubated for
5 min at 37°C after alkalinization with NaOH to allow
cleavage of the thiolactone ring. For the measurement of
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final assay mixture contained 0.5 mmol/L SAM. The final
assay mixture (total volume 50 μL) was incubated at 37°C
for 4 h or was stopped immediately if a blank was
processed. The reaction was stopped by acidification of
the reaction mixture to pH 1-2 with 100 μL of Internal
Standard Solution (EZ:faast; Phenomenex, Torrance, USA)
containing 3.3 μmol/L of internal standard 3,3,4,4-
2H-
labeled cystathionine (CDN Isotopes,Quebec, Canada).
LC-MS/MS analysis
The CBS activity was determined by the LC-MS/MS measure-
ment of the product of enzyme reaction, 3,3-
2H-cystathionine,
using a commercially available kit for amino acid analysis (EZ:
faast; Phenomenex). Sample preparation according to the
manufacturer’s instruction involved a solid phase extraction
step, derivatization with propyl chloroformate, and an extrac-
tion into an organic solvent prior to LC-MS/MS analysis.
The LC-MS/MS analysis was performed on proprietary
EZ:faast AAA-MS column (250×2.0 mm) using LC and
MS settings described in EZ:faast user manual.
The retention time of cystathionine isotopes was 15.5 min;
total analysis time including regeneration of the column was
25 min. Detection of the analytes was carried out using
positive electrospray ionization technique and selected mul-
tiplereactionmonitoring.Theprecursor→producttransitions
for 3,3-
2H-cystathionine (enzyme reaction product; m/z
481.3→230.3), cystathionine (calibration standards; m/z
479.3→230.3) and 3,3,4,4-
2H-labeled cystathionine (inter-
nal standard; m/z 483.3→234.3) were monitored.
Standards, calibration curves and activity calculation
Quantitation of the product of enzyme reaction 3,3-
2H-
cystathionine, which is not commercially available, was
performed using cystathionine standard samples in the
concentration range 0–5 μmol/L; the individual calibration
points were 0, 0.25, 1 and 5 μmol/L. The calibration curve
was obtained by linear regression; the peak area ratio
(analyte/internal standard) was plotted against the analyte
concentration. For the activity calculations, the measurable
concentration of 3,3-
2H-cystathionine in the blank sample
(t=0) was subtracted from the concentration produced by
the enzyme reaction after incubation for 4 h.
Results
Human plasma exhibits CBS activity
With the employment of LC-MS/MS technology, we
introduced a modification of an enzyme assay previously
published (Janosik et al. 2009). We observed that
incubation of control plasma samples according to the
protocol described in “Materials and methods” resulted in
the formation of 3,3-
2H-cystathionine. The signals of the
product of the enzyme reaction, 3,3-
2H-cystathionine,
determined in the assay mixture after incubation of control
plasma and plasma from a CBS-deficient patient for 4 h
are shown in Fig. 1a, b, respectively. The signals of
3,3-
2H-cystathionine in the blank sample (control plasma,
incubation time = 0 h) and internal standard are shown in
Fig. 1c, d, respectively. The figures show a clearly higher
signal of 3,3-
2H-cystathionine determined in the assay
using control plasma sample compared to the signals
obtained by analysis of assay mixture with plasma from
the CBS-deficient patient. The appearance of the signal of
3,3-
2H-cystathionine in the blank sample could be partial-
ly explained by isotope contribution of unlabelled cys-
tathionine presented in the analyzed sample to the signal
of 3,3-
2H-cystathionine. Nevertheless, despite the occur-
rence of the product signal in the blank sample, the assay
performance allowed sufficient discrimination between
plasma samples with normal and low or undetectable
activities.
In order to confirm that the 3,3-
2H-cystathionine
formation was due to the presence of CBS in plasma, to
elucidate the source of the enzyme in circulation and to
validate the enzyme assay we performed experiments
described in the following section.
Demonstration of CBS protein in human plasma
by immunodetection and in silico searches
To demonstrate the presence of CBS antigen in plasma, we
first performed western blotting after immunoprecipitation
preceded by low abundant plasma protein enrichment.
Multiple fractions including bands of approximately 60
and 45 kDa which were consistent with the presence of full-
length and truncated forms of CBS were observed (data not
shown). To confirm the identity of these fractions, we used
gel digestion followed by peptide mass fingerprinting with
MALDI-TOF MS detection; only abundant serum proteins
such as albumin were identified with no peptide related to
CBS being detected (data not shown). These data suggested
that the fractions observed on western blots were due to the
presence of cross-reactive highly abundant plasma proteins.
In addition, we were unable to detect the CBS antigen by
ELISA as this in-house assay had poor sensitivity (see
Discussion).
As an alternative approach to demonstrate the presence
of CBS in human plasma, we searched the available
proteomic database Peptide Atlas (www.peptideatlas.org).
As of February 1, 2010, the search only identified the
presence of CBS peptides 2–18 and 414–439 in an
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(Liu et al. 2004), demonstrating that CBS is indeed present
in normal human plasma but in only very low quantities.
Responsiveness of plasma CBS activity
to S-adenosyl-L-methionine and pyridoxal 5′-phosphate
Since S-adenosyl-L-methionine (SAM) is an allosteric
activator and pyridoxal 5′-phosphate (PLP) is a cofactor
of human CBS, we tested whether the addition of these
compounds into the assay mixture would increase the
production of 3,3-
2H-cystathionine.
We performed the assays in plasma samples (n=6)
according to the protocol described in “Materials and
methods” with and without the addition of SAM (final
concentration in the assay was 0.5 mmol/L) to the assay
mixture. We observed that the addition of SAM to the
assay mixture increased the production of 3,3-
2H-cysta-
thionine by a factor of 2.2 ± 0.2. Similarly, the assay was
performed using control plasma samples (n=6) with and
without PLP added to the assay mixture. The production
of 3,3-
2H-cystathionine in the assay with PLP was 1.6 ±
0.1 times higher than without the cofactor added to the
assay. The stimulatory effect of both compounds on the
production of 3,3-
2H-cystathionine in the assay gives
further support to the hypothesis that human plasma
contains CBS activity.
Origin of CBS in human plasma
To explore the hypothesis that CBS is released into plasma
from organs with a high content of the enzyme, we
determined the enzyme activity in plasma samples obtained
from individuals with elevated biomarkers for liver (alanine
aminotransferase, ALT and aspartate aminotransferase,
AST), pancreatic (pancreatic amylase, p-AMS) and kidney
(creatinine) disease. The results, shown in the Supplemen-
tary Table, clearly demonstrated an extremely elevated CBS
activity (22463-231179 nmol/h/L) in plasma from individ-
uals with increased ALT (2.4-15 μkat /L) and AST (2.1-14
μkat/L). Elevation of CBS activity was present also in the
majority of plasma samples from individuals with elevated
creatinine and p-AMS, respectively, although the plasma
CBS activity increase was less striking than in patients with
elevated plasma aminotransferase activities. These data are
congruent with the hypothesis that CBS may be released
into plasma from organs with a high content of this
enzyme, mainly from liver.
Method validation
Assay linearity To determine the linearity of the assay we
incubated the assay mixture for different time intervals (1,
2, 4 and 6 h). In addition, three experiments assays were
performed with the addition of different plasma volumes to
Fig. 1 The LC-MS/MS chromatograms. Signal of 3,3-
2H-cystathio-
nine (retention time 15.4–15.5 min) was determined after incubation
of the assay mixture with control plasma (a incubation time 4 h, c
incubation time 0 h, sample blank), and a plasma from a CBS-
deficient patient (b incubation time 4 h). d The signal of the internal
standard 3,3,4,4-
2H-labeled cystathionine. The peak with retention
time 14.5 min belongs to an unknown compound, which is not a
product of the CBS-catalyzed reaction
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an incubation time 4 h. Product formation was measured
and plotted against different time points or varying plasma
volumes, respectively. In both experiments, we observed
linear relationships with correlation coefficients r
2=0.997
and r
2=0.999, respectively. The linearity of the time and
dose relationships supports the presumption that the moni-
tored compound, 3,3-
2H-cystathionine, is a product of the
enzyme reaction.
Intra- and Inter-day variation of the assay The assay
reproducibility was assessed by determination of intra-
and inter-day coefficients of variation of the assay. For
determination of the intra-day variation, the assay was
performed with 5 identical control plasma samples in 1 day.
For determination of the inter-day variation, the assays
were performed using the control plasma on six separate
days over an 11-month period. The mean of the activities
were determined and coefficients of variation (in parenthe-
ses) for intra- and inter-day experiments were 354 nmol/h/L
(1.4%) and 309 nmol/h/L (17 %), respectively. These data
show that reproducibility of this assay was satisfactory and
was consistent with the usually observed performance of
enzyme assays.
Sample stability Sample stability was assessed by assaying
control plasma immediately following venepuncture and
plasma separation, and after one and ten cycles of freezing
and thawing. In addition, samples were also tested
following incubation of plasma samples stored at 25°C for
6 h. No change in activity was seen after one freeze and
thaw cycle. However, after ten cycles, a decrease of 13% in
activity was observed. A similar decrease in activity (i.e.,
11%) was also observed after incubation of the plasma for
6 h at room temperature. The activity changes resulting
from freezing and thawing or sample storage at 25°C may
have contributed to the significantly higher inter-day
coefficient of variation.
Sample matrix effects The validation experiments described
were carried out on plasma with EDTA used as anticoagulant
because the majority of archived samples from CBS-deficient
patients available for this study were prepared with EDTA.
However,toexploretheinfluence ofothersamplematriceson
CBS activity, we performed the assay using plasma (from one
person) following blood being collected into EDTA- and
heparin-containing tubes and serum collection tubes. The
results showed similar activities in heparinized plasma
samples and serum, whereas the activity in EDTA-treated
plasma was substantially lower (∼22%) compared to the
activity determined in the other two matrices. In addition, we
evaluated the effect of haemolysis on CBS activity in plasma
samples from a control subject and from two CBS-deficient
patients with low (10 nmol/h/L) and undetectable enzyme
activity, respectively. Haemolysis in one aliquot of EDTA
blood was induced by a single cycle of freezing and thawing
before centrifugation. Haemolysis had no measurable effect
on plasma CBS activity.
CBS activities in plasma obtained from controls and CBS
deficient patients
To assess the clinical utility of the plasma CBS assay in
diagnosing patients with CBS deficiency, we measured
activities in plasma samples obtained from control subjects,
CBS-deficient patients and their parents. These samples
were obtained from four European countries (see Supple-
mentary Table and Fig. 2). The median plasma CBS
enzyme activity from control subjects (n=57) was
404 nmol/hour/L, the median plasma enzyme activity from
pyridoxine nonresponsive CBS deficient patients (n=26)
was 0 nmol/hour/L. The median plasma enzyme activity
from pyridoxine responsive patients (n=28) was 16 nmol/h/
L, higher than in the pyridoxine nonresponsive patients, but
compared to the median of control subjects, it represented
just 4% of the activity The median enzyme activities in the
heterozygote parents (n=9) was 547 nmol/h/L, showing no
utility of the assay to recognize heterozygotes.
Because of the elevation of plasma CBS activity
observed in samples from individuals with presumed liver
disease (see “Origin of CBS in human plasma”) the most
stable biomarker for the liver disease, γ-glutamyl transfer-
ase (GGT), was determined in archived samples analyzed in
this study. The samples with elevated levels of GGT (higher
than 0.8 μkat/L) showed increased CBS activity, i.e. higher
than 1,300 nmol/h/L, and were therefore excluded from the
control dataset. One pyridoxine responsive CBS deficient
patient had an elevated plasma GGT (1.5 μkat/L) and CBS
activity (770 nmol/h/L) and was also excluded from the
presented dataset.
Discussion
Utilization of mass spectrometry for determination of CBS
activity
The introduction of novel analytical techniques into routine
diagnostic laboratories in the last decade has opened up the
field for new approaches in enzyme assay methodology.
Tandem mass-spectrometry in enzymology allows the use
of substrates that are labeled with stable isotopes instead of
radioisotopes; its utility has been discussed elsewhere (Gelb
et al. 2006). In this study, we employed LC-MS/MS to
design a novel CBS assay, utilizing isotopically labeled
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2H- serine. This method has excellent
sensitivity and can detect nanomolar concentrations of the
reaction product, 3,3-
2H-cystathionine.
Compared to the previously described radiometric assay
using
14C serine with a detection limit in the low
micromolar range (Kopecka et al. 2010), the LC-MS/MS
method is at least 2 orders of magnitude more sensitive and
enables the determination of very low catalytic activities of
CBS in human plasma, which would be undetectable by the
established radiometric method. Using the radiometric
method, we were able to detect product of the CBS activity,
radioactive cystathionine, only in the sample from a patient
with the most severe liver disease (data not shown).
Is there any measurable CBS activity present in human
plasma?
Although CBS is an intracellular cytosolic enzyme, the
breakdown of tissue containing high amounts of this enzyme
may result in leakage of CBS protein into plasma, a
phenomenon commonly observed in the case of other liver
enzymes that are routinely measured in human plasma or
serum (e.g., ALT, AST, GGT and others). Our study has
shown that control human plasma is able to catalyze the
formation of cystathionine with a median activity (404 nmol/
h/L,i.e.125pkat/L)whichisthree tofiveordersofmagnitude
lower than activities of serum enzymes routinely used in
clinical chemistry. Several lines of evidence demonstrate that
thisactivitycanbeattributedtothepresenceofCBSinhuman
plasma: (1) the absence of activities in plasma samples from
pyridoxine nonresponsive CBS deficient patients and its
presence in controls; (2) activation of plasma CBS by SAM
and PLP by a factor of 2.2 and 1.6, respectively; (3)
configuration of the detected reaction product, 3,3-
2H-
cystathionine, is in agreement with the previously observed
CBS reaction mechanism (Banerjee and Zou 2005;B o r c s o k
and Abeles 1982;M i l e sa n dK r a u s2004); this mechanism
involves the formation of aminoacrylate intermediate with
release of water containing one deuterium atom bound
originally on the alpha-carbon of serine; and (4) the presence
of CBS protein in normal human plasma was demonstrated
by in silico search of a proteome database. Considering the
specific activity of purified CBS protein (150 units/mg
protein) and the plasma CBS activity in controls, we
estimated that the quantity of CBS in human plasma is
approximately in the range of nanograms per millilitre which
does not allow the confirmation of the CBS presence in
human plasma by western blotting.
Plasma CBS activity in CBS-deficient patients – utilization
of the assay in diagnosis and study of CBS deficiency
In our study, we measured CBS activities in plasma from
54 patients with CBS deficiency and 57 control subjects.
The range of activities in the plasma from pyridoxine
nonresponsive CBS-deficient patients was clearly separated
from the range obtained in plasma samples from control
subjects. In contrast, the range of activities in plasma from
pyridoxine responsive CBS-deficient patients overlaps with
those from the control subjects.
Fig. 2 CBS activities in plasma
samples. The graph shows
distribution of CBS activities
determined in plasma samples
obtained from pyridoxine
nonresponsive CBS deficient
patients (n=26), pyridoxine
responsive CBS deficient
patients (n=28), heterozygotes
for CBS deficiency (n=9) and
controls (n=57)
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diagnosis ofCBSdeficiency, we calculatedthe specificityand
sensitivity of the assay. Since the lowest CBS activity in
samples from control subjects was 67 nmol/h/L, this value
was used as a threshold value for differentiating patients from
controls. The sensitivity and specificity of the assay was
excellent for pyridoxine nonresponders (i.e., sensitivity =
100% and specificity = 100%), while it was suboptimal for
pyridoxine responders (i.e., sensitivity = 70% and
specificity = 100%). These data suggest that the plasma
CBS assay may be useful in detecting pyridoxine non-
responders, while its use for diagnosing responders may be
limited.
The reason for the wide range of plasma CBS activities
observed in pyridoxine responders (0-358 nmol/h/L) is
unknown. This variability is caused not only by the
underlying genetic defect but may result from a contribution
of additional and yet unknown factors (as demonstrated by a
wide range of plasma CBS activities in patients homozygous
for the c.833T>C mutation; see Supplementary Table). It is at
present unknown whether the CBS assay in plasma will be
useful for predicting the phenotypic severity in pyridoxine
responsive patients. The measurement of plasma CBS
activity may be useful to evaluate or monitor the effective-
ness of pyridoxine therapy. The latter hypothesis is
supported by an experiment in which it was observed that
plasma CBS activity in one patient increased from 4.5 to
55.9 nmol/h/L after the patient started pyridoxine therapy.
However, in two other samples from patients responding to
pyridoxine therapy, the activity was undetectable before as
well as after the start of pyridoxine treatment (data not
shown). Evaluation of the effects of pyridoxine therapy on
plasma CBS activity would require further studies on
patients before and on therapy.
To our knowledge, this is the first report demonstrating
the presence of CBS activity in human plasma. This proof-
of-principle study shows that very low catalytic activities of
enzymes originating from liver can be measured in cell-free
extracellular fluids. In summary, this paper highlights the
possibility of measuring intracellular enzymes in plasma or
serum using isotopically labeled substrates and LC-MS/MS
instrumentation, and opens new possibilities for diagnosing
other inborn errors of metabolism.
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